Meeting
2013 ASCO Annual Meeting
The cost implications of prostate cancer screening in the Medicare population.
Authors
Xiaomei Ma
Yale School of Medicine, New Haven, CT
Xiaomei Ma , Rong Wang , Jessica B. Long , Joseph S. Ross , Pamela R. Soulos , James B. Yu , Danil V. Makarov , Heather Taffet Gold , Cary Philip Gross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Cost
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6549)
DOI
10.1200/jco.2013.31.15_suppl.6549
Abstract #
6549
Poster Bd #
12E
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
First Author: Paras Shah
Poster
2013 Genitourinary Cancers Symposium
PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease.
First Author: Hong Zhang
Poster
2024 ASCO Genitourinary Cancers Symposium
Rapid quantification of prostate specific antigen (PSA) from fingerstick (FS) blood.
First Author: Joseph Earl Thomas
Poster
2023 ASCO Annual Meeting
The performance of prostate specific antigen (PSA) testing in the population based NPCC cohort.
First Author: Jan Oldenburg